Pfizer Inc. (PFE)
| Market Cap | 130.59B |
| Revenue (ttm) | 62.46B |
| Net Income (ttm) | 7.88B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.38 |
| PE Ratio | 16.61 |
| Forward PE | 7.87 |
| Dividend | $1.72 (7.49%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 55,669,822 |
| Open | 22.82 |
| Previous Close | 22.79 |
| Day's Range | 22.51 - 23.09 |
| 52-Week Range | 20.92 - 31.54 |
| Beta | 0.50 |
| Analysts | Hold |
| Price Target | 30.36 (+32.17%) |
| Earnings Date | Apr 29, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for PFE stock is "Hold." The 12-month stock price forecast is $30.36, which is an increase of 32.17% from the latest price.
News
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projected Dividends
Earnings season saw strong reports from Microsoft, Apple, Meta, and Amazon, boosting the S&P 500 by 2.75% and the Nasdaq by 2.82%. The Dividend Harvesting Portfolio gained 1.98% this week, with a tota...
March/April Readers Tagged 7 Ideal Dividend Dogs From 12 'Safer' Of 36
Prior to April 30, 2025, my Readers mentioned 36 equities in their comments about my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers spoke-up about their ReFa...
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Build A 12%+ Yield On Cost By 2035 With May's Top 10 High-Yield Picks
In this article, I present 10 attractive high-yield investment options for this month of May 2025, which not only offer dividend income but also potential for dividend growth. The selection process in...
Pharma imports to US surged in March as drugmakers look to avoid tariffs
Pharmaceutical imports to the U.S. surged in March as drugmakers stocked up ahead of potential U.S. tariffs on their products, which have historically been exempt from such fees.
Pfizer Has Unreasonable Whiff Of The Marlboro Man
What makes Pfizer and Altria alike? They have trouble keeping their customers. Altria's dividend yield is 7%, even as it trades at 11 times estimated earnings over the next 12 months – a 40% premium t...
Trump Sets Pharma Tariffs Deadline. The Fallout for Eli Lilly, Pfizer, Other Drugmakers.
The president signed an executive order to promote domestic pharma production Monday, and said that news on drug tariffs will come within two weeks.
Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms
President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S. The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S.
2 Wonderful Dividends At Bargain Basement Prices
Market pessimism creates opportunity. Pfizer and Rexford Industrial trade at historically low valuations, offering high dividend yields and strong long-term growth potential. Pfizer's diversified drug...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (May 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Build Your Own ATM: 2 Undervalued Dividend Machines Yielding 7%
Predicting markets is nearly impossible, even with perfect foresight; reactions can defy logic. That's why I focus on strategy, not headlines. Recessions are often declared late. By then, stocks may a...
The GLP-1 Saga Continues, And How
Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are no longer considered to officially be in shortage.
Dividend Harvesting Portfolio Week 217: $21,700 Allocated, $2,179.74 In Projected Dividends
Alphabet's strong earnings and $75 billion capex reaffirmation set a bullish tone for big tech, boosting market confidence and economic outlook. The Dividend Harvesting Portfolio rose 2.46%, reaching ...
Pfizer's Q1 Update May Mark A Bottom In The Stock
Pfizer is facing some revenue pressures due to some higher Medicare discounts, and this has led to a small miss on revenue delivery in Q1 FY25. Pfizer is making meaningful improvements on profitabilit...
Pfizer's CEO said the company could make 'tremendous investments' in the US if Trump's tariffs go away
Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US.
Final Trade: XLF, ORLY, PFE, UBER
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Pfizer could make ‘tremendous investments' in the US, but here's why it's choosing not to
Pfizer Inc. (NYSE: PFE) chief executive Albert Bourla says uncertainty related to higher tariffs on pharmaceutical imports under the Trump administration is discouraging the company from investing in ...
Pfizer Inc. (PFE) Q1 2025 Earnings Call Transcript
Pfizer Inc. (NYSE:PFE) Q1 2025 Results Conference Call April 29, 2024 10:00 AM ET Company Participants Francesca DeMartino - Chief Investment Relations Officer and Senior Vice President Dr. Albert Bo...
Pfizer's 7% Yield Makes It Look Like a Junk Bond—But Better
The big decline in Pfizer's share price may have a silver lining.
Stocks on the move: Pfizer and Uber
Pfizer's down after earnings — and Josh Brown, CEO of Ritholtz Wealth Management, is making moves. Hear why he's trimming Pfizer and what he sees in Uber!
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
It comes as drugmakers brace for Trump's levies on pharmaceuticals imported into the U.S. – his administration's bid to boost manufacturing in the country.
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 250 points on Tuesday.
Breaking down Pfizer's first quarter earnings results, tariff impacts
Pfizer's (PFE) first quarter earnings were mixed, with sales coming in narrowly below Wall Street expectations. The pharmaceutical company has reaffirmed its 2025 outlook and announced plans for $1.2 ...
Pfizer's plunging Paxlovid sales impact revenue as COVID fades
Pfizer Inc.'s stock moved lower in premarket trading on Tuesday after the drugmaker fell short of Wall Street's revenue estimate, as sales of its COVID-19 medicine Paxlovid plunged by 75% on fading de...